IREN
IREN Limited
There isn't enough reported data to score IREN yet.
UVE
Universal Insurance Holdings, Inc.
UVE's fundamentals are strong and it looks cheap: trading at 6.1x earnings, below its usual 10x. Analysts expect earnings to fall sharply.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
UVE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
UVE's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like UVE.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
UVE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6.1x | $48.57 | — |
| Cheap | 7x | $55.89 | +15% |
| Fair | 10x | $82.24 | +69% |
| Forward | 13x | $48.57 | — |
| Expensive | 24x | $195 | +302% |
Historical ranges are pointers, not guarantees.
UVE's PE is in its cheap range at 6.1x. Analysts expect earnings to fall, which would put today's price at 13x next year's earnings, in its fair range.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IREN has the edge over UVE on the outlook, with more favorable revenue and profitability expectations.
UVE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect UVE's earnings and profitability to decline, with its revenue holding steady.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
UVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.88 | -51% |
| Q3 2026 | $8.00 | +89% |
| Q2 2026 | $7.58 | +231% |
| Q1 2026 | $6.75 | +195% |
| Q4 2025 | $6.31 | +217% |
| Q3 2025 | $4.24 | +72% |
| Q2 2025 | $2.29 | -19% |
| Q1 2025 | $2.29 | -10% |
| Q4 2024 | $1.99 | -9.5% |
UVE has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
UVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $439.3M | +9.6% |
| Q2 2026 | $427M | +6.7% |
| Q1 2026 | $393.6M | -0.3% |
| Q4 2025 | $407.9M | +6% |
| Q3 2025 | $401M | +3.5% |
| Q2 2025 | $400.1M | +5.2% |
| Q1 2025 | $394.9M | +7.3% |
| Q4 2024 | $384.8M | +2.5% |
UVE's revenue is growing: $439M last quarter, up 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +2.8 points |
| Q2 2026 | 19% | +7.1 points |
| Q1 2026 | 18% | +4.2 points |
| Q4 2025 | 22% | +20 points |
| Q3 2025 | 13% | +18 points |
| Q2 2025 | 12% | -1 points |
| Q1 2025 | 14% | +1.1 points |
| Q4 2024 | 1.9% | -5 points |
UVE has the edge over IREN on profitability, with a higher operating margin.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
UVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $82M | +34% |
| Q2 2026 | $100.2M | -4.8% |
| Q1 2026 | $153.2M | -17% |
| Q4 2025 | $25M | +$127.2M |
| Q3 2025 | $61.3M | -24% |
| Q2 2025 | $105.2M | +47% |
| Q1 2025 | $185.5M | +133% |
| Q4 2024 | -$102.2M | -$101.4M |
UVE has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
UVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +142K shares |
| 1 year | +1.3% | +377K shares |
| 3 years | -1.5% | -432K shares |
| 5 years | -6.9% | -2.2M shares |
| Available history | -15% | -5M shares |
UVE has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.5M |
| Q2 2026 | $4.5M |
| Q1 2026 | $7.1M |
| Q4 2025 | $6.9M |
| Q3 2025 | $8.1M |
| Q2 2025 | $7.4M |
| Q1 2025 | — |
| Q4 2024 | $7.7M |
UVE spent $26M buying back its own shares over the past year, up 12% from the year before.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
UVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.3x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -2.9x | Net Cash |
| Q1 2025 | -3.2x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
UVE has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like UVE.
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
UVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.3 | Neutral |
| Stochastic | 69.2 | Neutral |
UVE's weekly RSI is 66 (neutral) and its Stochastic is 69 (neutral).
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
UVE PE vs Financial Services Sector
| Metric | UVE | Sector median | Relative |
|---|---|---|---|
| PE | 6.1x | 13x | 53% below |
| PE % | 10 | 63 | 53 pts below |
UVE is trading at 6.1x earnings, a 53% discount to the Financial Services sector's median of 13x.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
UVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.5 | 4.5% above |
| 20 week MA | $44.3 | 9.5% above |
| 50 week MA | $38.5 | 26% above |
| 100 week MA | $31.7 | 53% above |
| 200 week MA | $24.6 | 98% above |
UVE has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.
UVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $14.8 | -47% |
| 2021 | $14.8 | $16.8 | +14% |
| 2022 | $16.8 | $11.0 | -35% |
| 2023 | $11.0 | $16.0 | +46% |
| 2024 | $16.0 | $20.6 | +29% |
| 2025 | $20.6 | $33.8 | +64% |
| 2026 YTD | $33.8 | $48.6 | +44% |
UVE has the edge over IREN on returns for 2026, with the stronger performance.